News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 677 results
January 2024
-
StatementRadioligand Therapy Supply Information
Find radioligand therapy (RLT) supply updates for the United States (US) from Novartis, including contact information for questions.
-
Media ReleaseNovartis expands production of Pluvicto® with addition of its largest and most advanced radioligand therapy manufacturing facility in IndianapolisFDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility…
December 2023
-
Media ReleaseNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥…
-
Media ReleaseLatest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissionsWith 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in…
-
Media ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHApproval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH…
November 2023
-
Media ReleaseNovartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to CrystallizationCompany Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 Novartis Media Relations E-mail: [email protected] North America Julie Masow …
-
Remembering men’s health this National Veterans and Military Families Month
Novartis honors veterans and military families this month, highlighting their support and raising awareness on men’s health, especially prostate cancer’s impact on veterans.
October 2023
-
Media ReleaseFDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decadeFDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A…
-
Media ReleaseNovartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centersUS FDA has classified drug shortage status as resolved1Novartis capacity to produce Pluvicto will continue to grow with anticipated expansions to the manufacturing network in the US and globally…
-
Media ReleaseNovartis Pluvicto® shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane settingPhase III PSMAfore trial with Pluvicto® met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per…
-
Media ReleaseFDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseasesFirst new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)1-6 Cosentyx…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 57
- › Next page